Principal Investigator
Izidore Lossos
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240178
Clinical Trial Summary
Phase II trial of Mosunetuzumab in patients with newly diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647